Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
about
Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.Novel camptothecin derivatives as topoisomerase I inhibitors.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Safety, tolerability, and phar ...... s in a bridging phase I study.
@ast
Safety, tolerability, and phar ...... s in a bridging phase I study.
@en
type
label
Safety, tolerability, and phar ...... s in a bridging phase I study.
@ast
Safety, tolerability, and phar ...... s in a bridging phase I study.
@en
prefLabel
Safety, tolerability, and phar ...... s in a bridging phase I study.
@ast
Safety, tolerability, and phar ...... s in a bridging phase I study.
@en
P2093
P2860
P356
P1476
Safety, tolerability, and phar ...... s in a bridging phase I study.
@en
P2093
Anjna Surath
Arani Chatterjee
Kasiram Katneni
Maddali L Srinivas
Ramesh Mullangi
Rao N V S Mamidi
Sangeeta Jiwatani
Srihari Uppalapati
Vijay V Upreti
P2860
P304
P356
10.1177/0091270004270225
P577
2005-04-01T00:00:00Z